 WATERTOWN, Mass., Jan. 28, 2021 GLOBE NEWSWIRE -- EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT, a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration wet AMD. 